The abstract is read at the publisher; the summary is JClub's.
Neoadjuvant nivolumab plus ipilimumab in early-stage resectable hepatocellular carcinoma is feasible and shows RECIST 1.1 objective responses in 25% (8/32) of patients.
- Why it matters: Survival benefits seen in advanced hepatocellular carcinoma leave uncertainty about whether immune checkpoint blockade can be safely delivered before surgery and whether it reshapes immunity and tumour biology.
- What they did: In PRIME-HCC, a single-arm phase 1b trial, adults with Child-Pugh A, ECOG 0–1 resectable disease received nivolumab 3 mg/kg on days 1 and 22 plus ipilimumab 1 mg/kg on day 1, then underwent liver resection. Safety was the primary endpoint, with paired tumour imaging mass cytometry/spatial transcriptomics and longitudinal ctDNA profiling.
- The result: Any-grade adverse events occurred in 94% and grade 3 treatment-related events in 9%, with 91% undergoing surgery; ctDNA absence after surgery was linked to improved 2-year recurrence-free survival (82% vs 29%, p=0·049).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.